The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.
Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients
Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients.
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to
